Dual-Targeting BAFF and IL-23A Compounds for Autoimmune Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune and inflammatory diseases, such as systemic lupus erythematosus, are limited in efficacy and require multiple medications, leading to increased side effects and costs, with no approved compounds targeting both BAFF and IL-23A simultaneously.

Innovation Solution

Development of compounds comprising specific polypeptides that bind to both BAFF and IL-23A, designed to inhibit both autoantibody and IL-23 axis-mediated end organ damage, offering a dual-targeting approach with improved pharmacokinetics and reduced dosing frequency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If multiple medications are used to treat autoimmune and inflammatory diseases, then treatment coverage is improved, but side effects and costs increase

Engineering Contradiction:

Improvetreatment efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines two separate therapeutic functions into a single compound by fusing a BAFF-binding domain and an IL-23A-binding domain into one molecule. This merging approach allows simultaneous inhibition of both BAFF and IL-23A pathways, achieving comprehensive treatment coverage while reducing the number of separate medications needed, thereby decreasing cumulative side effects and treatment costs.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a universal compound capable of binding to multiple targets (both BAFF and IL-23A) through integrated binding domains. This multi-functional molecule addresses multiple disease pathways simultaneously, replacing the need for multiple specialized medications and reducing the overall burden of treatment-related side effects.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If multiple medications are used to treat autoimmune and inflammatory diseases, then treatment coverage is improved, but treatment costs increase

Engineering Contradiction:

Improvetreatment efficacyVSAvoidtreatment cost

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

By merging BAFF and IL-23A binding capabilities into a single compound, the patent reduces the quantity of separate medications required for effective treatment. This consolidation decreases pharmaceutical costs, administration complexity, and overall treatment burden while maintaining comprehensive disease coverage.

Inventive Principle:

Principle #5Merging (Combining)

3Ease of operation

If current treatments target single cytokines, then treatment simplicity is maintained, but clinical response is limited

Engineering Contradiction:

Improvetreatment simplicityVSAvoidclinical response

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent creates a universal therapeutic compound that simultaneously targets both BAFF and IL-23A, delivering enhanced clinical response through multi-pathway inhibition. Despite the increased molecular complexity, the compound is administered as a single agent, maintaining treatment simplicity from the patient perspective while achieving superior therapeutic outcomes through dual mechanism of action.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS11884744B2Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof

Publication Date: 2024.01.30 BOEHRINGER INGELHEIM INT GMBH

AI summary

The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.